XSHE
000915
Market cap838mUSD
Oct 09, Last price
24.22CNY
1D
1.13%
1Q
-1.22%
Jan 2017
-25.26%
Name
Shandong WIT Dyne Health Co Ltd
Chart & performance
P/E
10.61
P/S
2.55
EPS
2.28
Div yield, %
10.44%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
4.12%
Revenues
2.23b
+4.40%
Net income
535m
+3.78%
CFO
1.27b
+36.78%
Dividend
Jul 01, 20262 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Wit Dyne Health Co., Ltd., founded on June 26, 1993, and headquartered in Jinan, China, dedicates its operations to the investigation, creation, and manufacture of pharmaceuticals and health solutions tailored for children. The company offers a wide array of products, which include vitamin A and D drops, effervescent granules containing compound calcium carbonate, licorice zinc granules, iron dextran granules, and pediatric ibuprofen suppositories. Its offerings further extend to specialized medications such as azithromycin granules, dimercaptosuccinic acid capsules, rifaximin dry suspension, and oral rehydration salt powder.
Key people
Xiaoping Zhu
Chairman of the Board · since 2025
Lifu Tan
Chief Financial Officer · since 2025
Jie Yang
General Manager, Director · since 2025
Ning Fang
Deputy General Manager · since 2012
Yinghua Gao
Deputy General Manager · since 2011
Shuwang He
Deputy General Manager, Director · since 2025
Ke Li
Deputy General Manager · since 2012
Longjiang Wang
Deputy General Manager · since 2025
Xuzhen Deng
Chief Engineer · since 2011
Liming Fan
Secretary of the Board · since 2025
Shucang Cheng
Director
Xinwei Wu
Director · since 2024
Ning Du
Independent Director
Cheng'an Liu
Independent Director · since 2024
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||